Nitinol is a near equiatomic nickel-titanium alloy whose pseudoelasticity and shape memory behavior enable cardiovascular and minimally invasive device designs that conventional metals cannot support [1]. The material appears in stents, heart valve frames, guidewires, and vena cava filters, with use expanding into other device areas [1]. Because thermomechanical behavior and processing sensitivity differ sharply from stainless steel, titanium, or cobalt-chrome alloys, FDA recommends that premarket submissions include nitinol-specific technical information [1]. This article explains the concrete documentation and testing workflows that support a nitinol device program, distinguishes material variants by melt route and inclusion content, and identifies where current evidence leaves open questions. The focus is non-clinical assessment, not patient care or clinical outcome claims. ## What FDA Expects in a Nitinol Premarket Submission

FDA's 2021 technical guidance describes the type of information the agency recommends including in a premarket submission of a device made from nitinol [1]. The appropriate submission type depends on the regulatory classification of the device, and the amount of data needed varies with device design, intended use, and classification [1]. When a device contains multiple types of nitinol, such as components with different surface finishes, FDA recommends that the suggested information be supplied for each type [1]. Device-specific guidance documents may add further technical recommendations where available [1].

Surface processing steps deserve particular attention because FDA states that surface processing can have a significant effect on the corrosion and nickel leach performance of nitinol [1]. FDA recommends a detailed description of honing, microblasting, pickling, polishing, or passivation so corrosion and nickel release risk can be evaluated [1]. FDA also recommends describing final post-processing cleaning steps and discussing how those steps are designed to remove surface residuals that could impact biocompatibility [1]. This documentation recommendation means a nitinol program cannot treat surface finishing as a downstream manufacturing detail; it is part of the regulatory evidence package.

ASTM Standards as the Shared Specification Language

ASTM F2063-18 is described by Resonetics as the foundational material specification for wrought nickel-titanium shape memory alloys used in medical devices and surgical implants [7]. According to Resonetics, it applies to wrought NiTi mill products including bar, flat rolled products, and tube containing nominally 54.5 to 57.0 weight percent nickel, and it establishes chemical, physical, mechanical, and metallurgical requirements [7]. Resonetics states that finished cold-worked tube is directed to ASTM F2633-19, which sets chemical, mechanical, dimensional, and surface-condition requirements for drawn medical-grade tube [7]. According to Resonetics, F2633 relies on F2063 for applicable material requirements and uses F2516-style definitions to set minimum property expectations for tube [7].

ASTM F2516-22 is described by Resonetics as the tensile test method standard for characterizing superelastic nitinol behavior [7]. According to Resonetics, it includes methods for determining upper plateau strength, lower plateau strength, residual elongation, tensile strength, and elongation [7]. The distinction matters in practice: Resonetics describes F2063 as a material specification, F2516 as a test method, and F2633 as a product-specific tube specification that bridges the two [7]. A device program that cites only F2063 chemistry without F2516 tensile characterization has not yet established the mechanical property evidence that tube-level specifications expect, according to the Resonetics description of how the standards relate [7].

A Suggested Evaluation Workflow for a Hypothetical Heart Valve Frame Program

Consider a hypothetical engineering team evaluating nitinol tube for a transcatheter heart valve frame. A structured approach could begin by confirming that the supplied tube meets ASTM F2063 chemistry and ASTM F2633 dimensional and mechanical requirements, then characterizing transformation temperatures by differential scanning calorimetry or bend and free recovery [7][5]. The team could then request inclusion analysis and microstructural characterization, since inclusion size and area fraction differ by melt route according to Fort Wayne Metals [6][7].

For fatigue evidence, the team could use FDA's RST24OP01.01 to estimate the low-to-high cycle fatigue transition before committing to ASTM F3211 load levels [2]. If the device operates across multiple mean strains, the team might review the VAR/EBR study's reported 10^8-cycle fatigue strain limits at mean strains between 3 and 5 percent, while recognizing that the study material's inclusion threshold below 10 micrometers is not identical to every commercial specification [3]. Finally, the team could document surface processing steps and sterilization compatibility testing per ASTM F2129, as FDA guidance and the sterilization study describe [1][8]. This workflow is a suggestion for organizing evidence, not a validated test plan or a claim that any specific material will pass.

Melt Route and Inclusion Content: Gen I Versus Gen II

Fort Wayne Metals states that two generations of material variants dominate the current market [6]. According to Fort Wayne Metals, Gen I finishes with the vacuum arc remelting, or VAR, process and meets ASTM F2063 requirements, which permit maximum inclusion sizes of 39 micrometers and area fractions up to 2.8 percent [6]. Fort Wayne Metals describes Gen II as produced by premium melting processes such as plasma arc melting, or PAM, which uses a plasma torch in a pressurized inert atmosphere to prevent carbon contamination and better control ingot structure [6]. Fort Wayne Metals states that Gen II yields maximum inclusion sizes of 20 micrometers or less and inclusion area fractions held to 1.5 weight percent or below [6].

Fort Wayne Metals attributes Gen I to standard stents and positions Gen II, with smaller and fewer inclusions, for more demanding applications [6]. The company's Altus Nitinol variant tightens the area fraction limit further to 1.2 weight percent [6]. This is a vendor characterization, not an independent regulatory ranking. A separate open-access study describes vacuum arc remelted and electron beam refined, or VAR/EBR, nitinol with inclusion sizes below 10 micrometers tested to 100 million cycles [3]. That study reports up to 275 percent improvement in 10^8-cycle fatigue strain limit compared to conventional VAR nitinol at mean strains between 3 and 5 percent [3]. The two sources use different inclusion thresholds and processing routes, so direct numerical comparison between Fort Wayne Metals' Gen II and the VAR/EBR study material is not supported by the public information.

Fatigue-to-Fracture Planning and the Low-to-High Cycle Transition

FDA's regulatory science tool RST24OP01.01 outlines a strategy for estimating the transition from low to high cycle fatigue in nitinol to aid fatigue-to-fracture, or FtF, test planning [2]. The tool is intended to assist individuals selecting load levels for testing per ASTM F3211 for medical devices containing a nitinol component [2]. FDA's RST description notes that ASTM F3211-17 Section 6.8 states it is often desirable to conduct FtF testing at multiple load levels to induce both fractures and run-outs [2]. The RST can estimate the transition, sometimes called the knee in a fatigue life diagram, without supplemental pilot or scoping fatigue tests [2].

The RST is only applicable to pseudoelastic nitinol because of its austenite-martensite phase transformation [2]. It may be used for entire devices, components, coupons, or surrogate samples as long as the cyclically loaded component is constructed from pseudoelastic nitinol [2]. FDA notes that prediction of phase transformation is sensitive to mesh resolution, and mesh refinement studies are recommended to increase accuracy [2]. The tool is intended to be used with ASTM F3211-17 and ASTM F2516-18 [2]. This means the RST is a planning aid, not a substitute for the underlying fatigue testing or for computational stress and strain analyses described in the FDA nitinol guidance [2].

Sterilization Compatibility and Corrosion Evidence

A 2024 study examined nitinol compatibility with vaporized hydrogen peroxide and nitrogen dioxide sterilization [8]. Test samples included nonpassivated and passivated nitinol, with passivated samples receiving an additional passivation step [8]. Samples were exposed to one, two, or six sterilization cycles, and the high-exposure groups were treated as worst case for corrosion resistance because they had the most sterilization environment exposure time [8]. Electrochemical testing followed ASTM F2129-19a [8].

The study reports that worst-case test results did not show any difference compared with nonsterile control samples, and Eb minus Er values were similar before and after sterilization [8]. SEM-EDS scans indicated elemental composition in line with ASTM F2063 standards, with manufacturer specifications typically reporting 54.5 to 57.0 percent nickel and 45.5 to 43.0 percent titanium [8]. The authors concluded that nitinol showed promising results for compatibility with VH2O2 and NO2 sterilization [8]. This conclusion is limited to the surface morphology and corrosion resistance properties measured in the study; it does not establish clinical performance.